216 related articles for article (PubMed ID: 20331505)
21. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals.
Lee MS; Hsu CC; Wahlqvist ML; Tsai HN; Chang YH; Huang YC
BMC Cancer; 2011 Jan; 11():20. PubMed ID: 21241523
[TBL] [Abstract][Full Text] [Related]
22. Metformin in the prevention of hepatocellular carcinoma in diabetic patients: A systematic review.
Cunha V; Cotrim HP; Rocha R; Carvalho K; Lins-Kusterer L
Ann Hepatol; 2020; 19(3):232-237. PubMed ID: 31836424
[TBL] [Abstract][Full Text] [Related]
23. Cancer risk in HBV patients with statin and metformin use: a population-based cohort study.
Chen CI; Kuan CF; Fang YA; Liu SH; Liu JC; Wu LL; Chang CJ; Yang HC; Hwang J; Miser JS; Wu SY
Medicine (Baltimore); 2015 Feb; 94(6):e462. PubMed ID: 25674734
[TBL] [Abstract][Full Text] [Related]
24. Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish.
de Oliveira S; Houseright RA; Graves AL; Golenberg N; Korte BG; Miskolci V; Huttenlocher A
J Hepatol; 2019 Apr; 70(4):710-721. PubMed ID: 30572006
[TBL] [Abstract][Full Text] [Related]
25. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis.
Zhang H; Gao C; Fang L; Zhao HC; Yao SK
Scand J Gastroenterol; 2013 Jan; 48(1):78-87. PubMed ID: 23137049
[TBL] [Abstract][Full Text] [Related]
26. Asarone and metformin delays experimentally induced hepatocellular carcinoma in diabetic milieu.
Das BK; Choukimath SM; Gadad PC
Life Sci; 2019 Aug; 230():10-18. PubMed ID: 31121175
[TBL] [Abstract][Full Text] [Related]
27. Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma.
Schulte L; Scheiner B; Voigtländer T; Koch S; Schweitzer N; Marhenke S; Ivanyi P; Manns MP; Rodt T; Hinrichs JB; Weinmann A; Pinter M; Vogel A; Kirstein MM
Liver Int; 2019 Apr; 39(4):714-726. PubMed ID: 30663219
[TBL] [Abstract][Full Text] [Related]
28. Survival Advantage Associated with Metformin Usage in Hepatocellular Carcinoma Patients Receiving Radiotherapy: A Propensity Score Matching Analysis.
Jang WI; Kim MS; Lim JS; Yoo HJ; Seo YS; Han CJ; Park SC; Kay CS; Kim M; Jang HS; Lee DS; Chang AR; Park HJ
Anticancer Res; 2015 Sep; 35(9):5047-54. PubMed ID: 26254406
[TBL] [Abstract][Full Text] [Related]
29. Anti-tumor effects of metformin in animal models of hepatocellular carcinoma: a systematic review and meta-analysis.
Li J; Hernanda PY; Bramer WM; Peppelenbosch MP; van Luijk J; Pan Q
PLoS One; 2015; 10(6):e0127967. PubMed ID: 26030161
[TBL] [Abstract][Full Text] [Related]
30. Long-term metformin use may improve clinical outcomes in diabetic patients with non-alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis.
Vilar-Gomez E; Vuppalanchi R; Desai AP; Gawrieh S; Ghabril M; Saxena R; Cummings OW; Chalasani N
Aliment Pharmacol Ther; 2019 Aug; 50(3):317-328. PubMed ID: 31157422
[TBL] [Abstract][Full Text] [Related]
31. Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.
Massarweh NN; El-Serag HB
Cancer Control; 2017; 24(3):1073274817729245. PubMed ID: 28975830
[TBL] [Abstract][Full Text] [Related]
32. Diabetes mellitus and metformin in hepatocellular carcinoma.
Fujita K; Iwama H; Miyoshi H; Tani J; Oura K; Tadokoro T; Sakamoto T; Nomura T; Morishita A; Yoneyama H; Masaki T
World J Gastroenterol; 2016 Jul; 22(27):6100-13. PubMed ID: 27468203
[TBL] [Abstract][Full Text] [Related]
33. Hepatocellular carcinoma.
Llovet JM; Zucman-Rossi J; Pikarsky E; Sangro B; Schwartz M; Sherman M; Gores G
Nat Rev Dis Primers; 2016 Apr; 2():16018. PubMed ID: 27158749
[TBL] [Abstract][Full Text] [Related]
34. Metformin and cancer hallmarks: shedding new lights on therapeutic repurposing.
Hua Y; Zheng Y; Yao Y; Jia R; Ge S; Zhuang A
J Transl Med; 2023 Jun; 21(1):403. PubMed ID: 37344841
[TBL] [Abstract][Full Text] [Related]
35. Metformin promotes ferroptosis and sensitivity to sorafenib in hepatocellular carcinoma cells via ATF4/STAT3.
Hu Z; Zhao Y; Li L; Jiang J; Li W; Mang Y; Gao Y; Dong Y; Zhu J; Yang C; Ran J; Li L; Zhang S
Mol Biol Rep; 2023 Aug; 50(8):6399-6413. PubMed ID: 37326750
[TBL] [Abstract][Full Text] [Related]
36. Action Mechanism of Metformin and Its Application in Hematological Malignancy Treatments: A Review.
Zhang Y; Zhou F; Guan J; Zhou L; Chen B
Biomolecules; 2023 Jan; 13(2):. PubMed ID: 36830619
[TBL] [Abstract][Full Text] [Related]
37. Recent Insights of Metformin on Hepatocellular Carcinoma (HCC).
Wang K; Zhang K; Zhang X; Chen D; Jiang S
Mini Rev Med Chem; 2023; 23(11):1154-1166. PubMed ID: 35747976
[TBL] [Abstract][Full Text] [Related]
38. Metformin inhibits hepatocellular carcinoma development by inducing apoptosis and pyroptosis through regulating FOXO3.
Shen Z; Zhou H; Li A; Wu T; Ji X; Guo L; Zhu X; Zhang D; He X
Aging (Albany NY); 2021 Sep; 13(18):22120-22133. PubMed ID: 34546972
[TBL] [Abstract][Full Text] [Related]
39. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects.
Tang W; Chen Z; Zhang W; Cheng Y; Zhang B; Wu F; Wang Q; Wang S; Rong D; Reiter FP; De Toni EN; Wang X
Signal Transduct Target Ther; 2020 Jun; 5(1):87. PubMed ID: 32532960
[TBL] [Abstract][Full Text] [Related]
40. The mechanisms of action of metformin.
Rena G; Hardie DG; Pearson ER
Diabetologia; 2017 Sep; 60(9):1577-1585. PubMed ID: 28776086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
